Metformin is Contraindicated at eGFR <30 mL/min/1.73 m²
Metformin must be discontinued and should not be initiated when the estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m² 1, 2, 3. This represents a firm contraindication based on the risk of metformin accumulation and potentially fatal lactic acidosis.
eGFR-Based Dosing Algorithm
The management of metformin should follow this structured approach based on kidney function:
eGFR ≥60 mL/min/1.73 m²
- No dose adjustment required
- Continue standard dosing (up to 2550 mg daily in divided doses)
- Monitor eGFR at least annually 1, 2
eGFR 45-59 mL/min/1.73 m²
- Continue current dose in most patients
- Consider dose reduction in certain high-risk conditions (see below)
- Increase monitoring frequency to every 3-6 months 1, 2
- Do not initiate metformin in this range according to FDA guidance 4, 3
eGFR 30-44 mL/min/1.73 m²
- Reduce dose to half of maximum recommended dose 1, 2
- Maximum daily dose should not exceed 1000 mg 5
- Do not initiate metformin if patient is not already taking it 1, 4, 3
- Monitor eGFR every 3-6 months 1, 2
eGFR <30 mL/min/1.73 m²
- Absolute contraindication—stop metformin immediately 1, 4, 2, 3
- Never initiate therapy at this level
- Risk of lactic acidosis increases substantially 6, 7, 8
Critical Evidence Supporting the eGFR <30 Threshold
The most recent and authoritative guidelines consistently establish eGFR <30 mL/min/1.73 m² as the contraindication threshold. The KDIGO 2022 guideline 2 provides the strongest recommendation (Grade 1B), stating metformin should be used in patients with eGFR ≥30 mL/min/1.73 m² and explicitly contraindicated below this level. This is reinforced by FDA labeling 3, which states metformin is contraindicated when eGFR is less than 30 mL/min/1.73 m².
Real-world evidence supports this threshold: a large community-based cohort study of over 75,000 patients found metformin was associated with increased risk of acidosis only at eGFR <30 mL/min/1.73 m² (adjusted HR 2.07; 95% CI 1.33-3.22), but not at eGFR 30-44 mL/min/1.73 m² (adjusted HR 1.09; 95% CI 0.83-1.44) 6.
Important Caveats and Temporary Discontinuation
Contrast Imaging Procedures
Temporarily discontinue metformin at the time of or before iodinated contrast procedures if 4, 3:
- eGFR is 30-60 mL/min/1.73 m²
- History of liver disease, alcoholism, or heart failure
- Intra-arterial contrast administration planned
Re-evaluate eGFR 48 hours post-procedure before restarting 4, 3.
Sick-Day Rules
Stop metformin temporarily during acute illness that increases risk of acute kidney injury, including 9:
- Surgery or procedures requiring NPO status
- Severe dehydration or volume depletion
- Acute heart failure or hemodynamic instability
- Sepsis or severe infection
- Hypoxic states
High-Risk Populations Requiring Extra Caution
Even with eGFR 45-59 mL/min/1.73 m², consider dose reduction in patients with 1, 2, 3:
- Age ≥65 years (assess renal function more frequently)
- Hepatic impairment (avoid use with active liver disease)
- Excessive alcohol intake
- Heart failure
- Conditions causing tissue hypoxia
Monitoring Requirements
- Vitamin B12 levels: Check periodically, especially after 4+ years of metformin use, as deficiency can develop and worsen neuropathy 1, 2, 10
- eGFR monitoring frequency 1, 2:
- At least annually if eGFR ≥60
- Every 3-6 months if eGFR <60
- More frequently in elderly or those at risk for renal decline
Why eGFR, Not Serum Creatinine
The shift from serum creatinine cutoffs (previously <1.4 mg/dL for women, <1.5 mg/dL for men) to eGFR-based dosing is critical because eGFR accounts for age, sex, and race, providing more accurate assessment of kidney function 4, 11. Using eGFR expands the population who can safely receive metformin, particularly non-Hispanic Black patients and men, while more accurately identifying those at risk 11.
The bottom line: eGFR <30 mL/min/1.73 m² is the absolute contraindication threshold for metformin, with dose reduction required at eGFR <45 mL/min/1.73 m² and initiation not recommended below 45 mL/min/1.73 m².